<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211214053405N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-01</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of Pistacia atlantica oleoresin on Irritable bowel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of Pistacia atlantica oleoresin on clinical symptoms of the patients with Irritable bowel syndrome with constipation predominance</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-01-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60781</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is done by permuted block randomization method and concealment is done. Patients are divided into two groups using the above method. Six of the four combinations of intervention groups A and B are determined AABB ABAB ABBA ABBA BBAA BABA BAAB and randomly select each of the above combinations and those who agree to participate in the study are placed in study groups, Blinding description: In this study, blinding will be double-blind. In this way, patients will not be aware of their position in the two groups and the drug and placebo will be prepared in identical forms (in terms of color, smell, and taste) in the form of capsules for both groups. P. atlantica oleoresin capsules are delivered to the intervention group, and placebo capsules containing starch are delivered to the control group. The researcher responsible for collecting the initial data and the outcomes will not be aware of the type of drug the patients are taking.</study_design>
      <phase>3</phase>
      <hc_freetext>Irritable bowel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: P.atlantica oleoresin capsule (Saqez) and placebo are prepared by a pharmacist in the traditional pharmacy laboratory of the Faculty of Traditional Medicine of Babol University of Medical Sciences.  oleoresin is prepared in capsules weighing 500 mg. Tests are performed to control microbial and chemical analysis of the essential oil. Both drug and placebo are packaged in similar containers. The drug is taken twice a day for six weeks. Intervention 2: Control group: The placebo capsule is prepared by a pharmacist in the traditional pharmacy laboratory of the Faculty of Traditional Medicine of Babol University of Medical Sciences. The placebo capsules are filled with cornstarch (weighing 500 mg). Tests to control microbial contamination are performed. Both products are packaged in similar containers. To match the odor, placebo capsules are placed for a while in an area adjacent to P.atlantica essential oil. The placebo is taken twice a day for six weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The decision is made after negotiations with the sponsor</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amir Adibifard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ganjafrooz st</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4717647745</zip>
        <telephone>+98 21 7790 8363</telephone>
        <email>Amiradibifard@yahoo.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Narjes Gorji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ganjafrooz</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>47176-47745</zip>
        <telephone>+98 11 3219 4730</telephone>
        <email>N.gorji@mubabol.ac.ir</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patient has not been treated with Pistacia atlantica oleoresin for the past month
Patients with IBS whose type of disease has been confirmed by a complete medical examination.
The patient signs a written consent
Age over 18 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant or lactating women
Patients with malignancies or other chronic gastrointestinal diseases such as inflammatory bowel disease and celiac disease
History of major gastrointestinal surgery (including Billroth surgery, ostomy, and any resection in any part of the gastrointestinal tract).
Inability to swallow capsules
People taking psychotherapy drugs
Patients at a serious health risk, including severe heart, liver or kidney disease
Patients with severe plant allergies
Regular use of drugs that change the movement of the gastrointestinal tract such as metoclopramide, cisapride, drugs, diphenoxylate, etc.
Regular use of laxatives
Follow the diet plans with daily and regular intake of prebiotic/probiotic compounds
Taking antibiotics
The patient has been treated with Pistacia atlantica for the past month
Cigarette smoking, alcohol usage
NSAID usage</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K58.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Irritable bowel syndrome without diarrhea</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: P.atlantica oleoresin capsule (Saqez) and placebo are prepared by a pharmacist in the traditional pharmacy laboratory of the Faculty of Traditional Medicine of Babol University of Medical Sciences.  oleoresin is prepared in capsules weighing 500 mg. Tests are performed to control microbial and chemical analysis of the essential oil. Both drug and placebo are packaged in similar containers. The drug is taken twice a day for six weeks.</i_keyword>
      <i_keyword>Control group: The placebo capsule is prepared by a pharmacist in the traditional pharmacy laboratory of the Faculty of Traditional Medicine of Babol University of Medical Sciences. The placebo capsules are filled with cornstarch (weighing 500 mg). Tests to control microbial contamination are performed. Both products are packaged in similar containers. To match the odor, placebo capsules are placed for a while in an area adjacent to P.atlantica essential oil. The placebo is taken twice a day for six weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Change in the severity of irritable bowel syndrome based on the total score of the IBS-SSS scale. Timepoint: The beginning of the study and the sixth week of the intervention and one month after the intervention. Method of measurement: Irritable Bowel Syndrome Severity Questionnaire (IBS-SSS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life based on change in total score of IBS-QOL quality of life questionnaire, change in symptoms of IBS-SSS Irritable Bowel Syndrome Scale. Timepoint: Initially study and the sixth week of intervention and one month after intervention. Method of measurement: Quality of Life Questionnaire for Patients with Irritable Bowel Syndrome (IBS-QOL).</sec_outcome>
      <sec_outcome>The severity of symptoms subsets of the IBS-SSS Irritable Bowel Syndrome questionnaire. Timepoint: Initially study and the sixth week of intervention and one month after intervention. Method of measurement: IBS-SSS questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-06</approval_date>
        <contact_name>Ethics committee of Babol University of Medical Sciences</contact_name>
        <contact_address>Babol ganjafrooz st Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
